What the Mayo Clinic is learning from blood clot tests in allergic reactions
Official title: Maximum Lysis on Thromboelastography as a Marker of Systemic Severity in Acute Allergic Reactions
Run by Mayo Clinic · NCT07905911 · Data updated 2026-11-12
This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | October 23, 2026 |
| Main results expected | September 2030 |
| Study ends | September 2031 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07905911 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 12 years or older presenting to the emergency department with suspected allergic reactions, anaphylaxis, or angioedema where thromboelastography can be performed.
✕Probably not a fit
Patients whose reactions do not involve measurable differences in thromboelastography or who do not undergo timely TEG testing may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes thromboelastography measurements taken during acute allergic reactions, including suspected anaphylaxis or angioedema, to explore how maximum lysis relates to systemic severity. Researchers aim to combine these physiologic markers with future molecular data to identify endotypes and improve risk stratification. The study is centered at Mayo Clinic in Rochester, Minnesota, and uses thromboelastography (TEG) as the primary biomarker tool. No intervention beyond the blood test is used, and the design focuses on observation of biomarker patterns during acute presentations. The findings could inform biologically informed approaches to predicting outcomes in allergic reactions.
Why it matters
Potential benefit: If successful, the study could help clinicians predict which patients are at higher risk during an allergic reaction using blood-test results.
How similar studies have gone: Previous research has explored thromboelastography in various bleeding and coagulopathy contexts, but its use as a biomarker for allergic reaction severity is a newer, exploratory area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 12 years or older. * Presentation to the emergency department with suspected allergic reaction, anaphylaxis, or angioedema based on chief concern. * Ability to obtain thromboelastography during the acute presentation. Exclusion Criteria: * Known inherited coagulation or fibrinolytic disorders. * Active major bleeding at presentation. * Receipt of thrombolytic therapy. * Inability to obtain thromboelastography promptly.
Where it's running
-
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Ronna Campbell, MD — Mayo Clinic
- Study coordinator: Study Coordinator
- Email: vanmeter.derek@mayo.edu
- Phone: 507-255-5056
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Immune biomarkers to predict complications after liver transplantation
This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.
-
Biomarkers That Signal Silent Strokes in High-Risk Cardiac Procedures
This study tests whether blood biomarkers NSE and NFLs can predict silent brain injuries and later cognitive problems in adults having high-risk transcatheter heart procedures.
-
Does having allergic parents raise the chance of bronchiolitis in babies by 12 months?
We’re testing if infants with at least one allergic parent are more likely to have bronchiolitis by 12 months compared to infants whose parents have no allergies.
-
Centenarian cohort in Navarre to study aging and longevity
This study tests what factors help centenarians in Navarre stay healthier as they age and what might explain their exceptional longevity.
-
Using alpha-gal KO pork to see if it reduces reactions in people with Alpha-gal Syndrome
This study tests whether eating pork that lacks the alpha-gal allergen lowers reaction risk for people with Alpha-gal Syndrome, using a crossover design where each participant tries both KO and wild-type pork on separate days.
-
Using blood eosinophil counts to guide asthma care in primary care
This trial tests whether using blood eosinophil counts to guide treatment can reduce exacerbations and improve symptoms and quality of life for adults with mild to moderate asthma managed in primary care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.